Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Forbius Announces the First Patient Dosed in a Phase 1 Oncology Trial of AVID200

americanpharmaceuticalreviewJanuary 10, 2019

Tag: trial , Forbius , oncology , AVID200 , immunosuppression

PharmaSources Customer Service